»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ wbi3lH:;
8;#AO8+U7)
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 b+@D_E-RJ
MCU9O
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© (ua q<Cvg
1.Antigen presenting cell£¨APC£© k|FSz#Y
2.Activation induced cell death£¨AICD£© w^{!U
3.Chemokine L2fVLKH
4.Major histocompatibility complex£¨MHC£© \zu}\{
5.immunotolerance k)":v3^
`f)(Y1%.
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© 3taa^e.
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ AmcC:5
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà \H4U8)l
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ t3b@P4c\
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ kH?#B%N5
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã A-wRah.M
Np2ci~"<.
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© {DBIonY];
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ /\E [
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ KDey(DN:
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ ."mlSW
"Wm
vM4<d>
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ f=aIXhiYU
8h.V4/?
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 (C S
8(C4[
B QjGv?p0s
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ FifbxL
1.Antigenic determinant :a3xvN-l
2.IgSF <1@
(ioPH
3.MBL;¾¶ {1~T]5
4.chemokine P5?<_x0v4b
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ ?CY1]d
6.TCR-CD3¸´ºÏÎï G/{
~_&t
7.FADD£¨Fas-associated protein with death domain£© #I%s3
8.AIDS <DZcra
9.Tumor rejection antigen '
*R%^RK
10.AICD 7SS07$B
Rs7|}Dl}
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ %Kto.Xq
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© =+oZtP-+o
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ ~<r
i97)
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ `\b+[Nes
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì o""~jc~
p;%<mUI
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ +>YfRqz:KB
BHr|.9g]%%
.
/m hu
רҵ¿Î ÃâÒßѧ 5Op_*N{V
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê qnIew?-*
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell !B^K[2`)N
5. Fc¦Å receptor 6. Cytokine wahZK~,EaY
¶þ¡¢ ÎÊ´ðÌâ 5w<A;f
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 MCnN^
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ ]WL|~mG
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ Tr .hmG U
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 FPv"N'/
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠG{lcYP
O
HL 8eD^
Zb(t3I>n
*g$i5!yM'
CL9yEy"V
jw>hk
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ GozPvR^/
Pe$6s:|NS
8 ws$k\>
רҵ¿Î ÃâÒßѧ a!,r46>$H
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê wCb(>pL0
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen HEY4$Lf(I
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin z2 hFn&
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test ~5OL6Bi-q
9. Hybridoma technic 10.Mitogen -5Utlos
11.Dentritic cell 12.Immunoproliferation u, kU$
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ `f`TS#V
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ ]<trA$ 0
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦ÓᣠlU.Kc
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ AEg(m<t
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ i[nF.I5*f
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ \3zj18(@8!
g>j| ]6
f =s&n}
z
G9|K
:td ~g;w
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ
&|o$=Ad
W!la -n
!m y8AWO'
רҵ¿Î ÃâÒßѧ eSy(~Y
Ò»¡¢ Ãû´Ê½âÊÍ x]4Kkpqm
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï ?S[Y:<R{:
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà 1~yZ T
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ e XV@.
¶þ¡¢ ÎÊ´ðÌâ *75YGD
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ q31>uF
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ \~DM
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ 6 "gj!/e
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ tw K^I6@
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ {|<"C?
+ ,4"
u
c:4P%({
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ uh3)0.nR
F jrINxL7^
|%7cdMC
רҵ¿Î ÃâÒßѧ >FF5x#^&c
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê ?u$u?j|N
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR
W6/ @W
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA >,5i60Q
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM ;`j/D@H
¶þ¡¢ ÎÊ´ðÌâ O<*5$,K9
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ 3=.Y,ENM;
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ &X>7n~@0
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ pbk$o{$`W
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ >)nS2bOE
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ -*ELLY[
gwB\<rzG
F2I 5qC/
~}9PuYaD@
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ]!"S+gT*C
GF<[ }
m@G i6
רҵ¿Î ÃâÒßѧ ,[rPe\w.z
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê }d
Ad$^
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule +%*&.@z_
5. Autogous mixed lymphoyte reaction #?O&
¶þ¡¢ ÎÊ´ðÌâ `#s#it'y
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ p.JXSn
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ S -&)p@4
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ)r6EW`$
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ -yH,5vD
S6i@"h5
Gpj*
V|J
m]Y;c_DO:
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ B|=|.qp$)
IzLF'F
(nSml,gU
רҵ¿Î ÃâÒßѧ p^)B0[P9
)q~DTR^z-
r|<DqTc6l
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê PH3 >9/H
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance @\P4/+"9
5. Delayed type hypersensitivity ;iYff N
¶þ¡¢ ÎÊ´ðÌâ K!z`
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ ]c)_&{:V
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ C|-pD
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ ^_+XDO
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷ÓᣠQ+q,!w8
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷Óᣠ+JyUe
T)~9Wac
`RRE(SiKU
M" lg%j
;az5ZsvN
D
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 8P' ana
?
zDa=7 J
Qeq5 gN]
רҵ¿Î ÃâÒßѧ q%YV$$c
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê nR;D#"p%
1. hypersensitivity 2. cluster of differentiation L5YnG_M&
3. adhesion molecules 4. supper antigen 5. split tolerance XMN:]!1J
¶þ¡¢ ÎÊ´ðÌâ vV?rpe|%
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ F/c$v
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ | t QiFC
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ p,g1eb|E
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ E.bi05l
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ #K\?E.9h
Y/ot3[
\G@wp5
sZgRt
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ `Mj}md;O"
רҵ¿Î ÃâÒßѧ ![6EUMx
Ò»¡¢ Ãû´Ê½âÊÍ vl Ez9/H
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å R8ONcG
5. GVHR K0+.q?8D|
¶þ¡¢ ÎÊ´ðÌâ tMx}*l|]
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷Óᣠ#:x4DvDkR
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ )D-c]+yt
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£ /e}#'
H
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ S"m cUU}}
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ r\6"5cQ=
FXdD4 X)
2L_6x<u'
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ s pLZ2]A
6(|d|Si *c
Mp$@`8X`
רҵ¿Î ÃâÒßѧ UM*jKi2]"
Ò»¡¢Ãû´Ê½âÊÍ #3=P4FUz.
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å 8N%Bn&
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ ^I6^g
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ B
\*@krI@
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ *1Z5+uVT[
Èý¡¢ ÎÊ´ðÌâ 5F|8?BkOL^
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ ,bE$| x'
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ 5m:i6,4
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà +|Hioq*,t
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ NC qo@vE
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ kU-t7'?4
ZR v"h/~
t&Os;x?To?
8n BL\{'B[
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ I]"96'|N
e^YHJ>@
:4)
Qt
רҵ¿Î ÃâÒßѧ :!;'J/B@..
Ò»¡¢Ãû´Ê½âÊÍ aq+Y7IR_
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó $P7iRM]
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ F["wDO
Èý¡¢ ÎÊ´ðÌâ GhY1k
";
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ 49Df?sx
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ 6<,dRn
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ U`Jy!x2m
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ ]u-]'P
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ \7MHaQvS
_mS!XF~`P
9%ii '{
Glq85S
3QSZ ZJ
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ MC0TaP
Ò»¡¢Ãû´Ê½âÊÍ {Y}dv`G#Iu
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï O9'x-A%
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó Uw-p758dD
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ 3'c\;1lhT
¶þ¡¢ ÎÊ´ðÌâ gx03xPeu
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ zL5d0_E9
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ /sR%]q
|L
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ E$a ?LFa6
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ Tj~IaU
/2{5;
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ I9o6k?$K
Ò»¡¢ Ãû´Ê½âÊÍ nFX_+4V2
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ EA.D}X C
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ o!Ev;'D
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© H7+Xs%
10¡¢ ÒõÐÔÑ¡Ôñ h0?2j)X_
¶þ¡¢ ÎÊ´ðÌâ VHOfaCE
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 =H0vE7 {*
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ V~G
Wl1#7
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 I"AYWo?
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ |o'Q62`%}
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. oHM
]
lcON+j
n}A\2bO
nfb]VN~(
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ,3v+PIcMM+
TUL
_TR
@L84>3O
רҵ¿Î ÃâÒßѧ 2)?(R;$,
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ "HD+rmUEH
1. Cytokines 2. adhesion molecules 3. graft versus host reaction g
]*
4. immunologic tolerance 5. Opsonization 4@ILw
Èý¡¢ ÎÊ´ðÌâ #5sD{:f`
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷Óᣠ)T907I|
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ z^o 1GY
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ A6<C-1
N}j
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ B}OY/J/*8
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ r%wA&FQ8U
z!=
P@b
va/m
~k|i
w&Dv8Wv+Oq
fQWI
w
8$xPex~2
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ JGiKBm;
O9v_y+M
+M
39e;
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ OwzJO
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ zHB_{(o7
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê Rg29
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ I^*'.z!4Q
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û 9D@$i<D:
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö z
`8cOK-
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð fi PIAT}
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ 1
Wg-x0R
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ wbbqt0un
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© nR
\'[~+
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ k>4qkigjc
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ ^jdL@#k00
#$S}3
o
U3;aLQ*
!Gs} tiMH
x!S;SU
.W\ve>;
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ X[C3&NX#_
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ uE_c4Hp
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ (Ha@s^?.C
huFz97?y(
Ò»¡¢ Ãû´Ê½âÊÍ 9>m%`DG*
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß -=$2p0"R
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò 2f, B$-#
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô ={(j`VSUX0
¶þ¡¢ÎÊ´ðÌâ *}b]rjsj
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ aA*9,
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì _v5t<_^N
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì V%L/8Q~
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ @_'OyRd8
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ <zfe}0
}F1s
tDx